ArticleOncology letters2025
Morphological, immunophenotypic and neuroradiological characteristics of primitive B-large cell diffuse lymphoma of the central nervous system: A retrospective cohort analysis.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Probable cavernous sinus-adjacent meningeal metastasis from esophageal squamous cell carcinoma: A case report.Oncology letters · 2026Article
- Cold agglutination as a pivotal diagnostic clue for Waldenström macroglobulinemia: A rare case report with diagnostic and therapeutic insights.Experimental and therapeutic medicine · 2026Article
- Rapid immunohistochemistry for intraoperative differentiation between high-grade gliomas and primary central nervous system lymphomas: a multicenter prospective study.Brain tumor pathology · 2026Article
- Administration of tirabrutinib suspension in a patient with primary central nervous system lymphoma: A case report.Oncology letters · 2026Article
- A case report and literature review of rare intracranial and extracranial dual-lesion diffuse large B-cell lymphoma with heterogeneous subtypes (GCB type + ABC type).Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primitive diffuse large B-cell lymphoma (PCNSL-DLBCL) accounts for 2-3% of all central nervous system (CNS) tumors, predominantly affecting supratentorial sites in adult patients. In the present study, the immunohistochemical (IHC) profile was analyzed in a cohort of 23 cases of CNS DLBCL to determine whether B-cell markers [CD20, CD79a and paired box 5 (PAX5)], BCL2, CD10, BCL6, MUM1 and c-Myc, as well as the Ki67 labeling index, were associated with the clinicopathological (age, sex and location) and neuroradiological (T1, T2, post-contrast and diffusion-weighted imaging) parameters of the patients. The Hans algorithm was applied to subtype DLBCLs into germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB). Univariate statistical analysis was performed using Fisher's exact test to identify statistically significant associations between clinicopathological, IHC and radiological variables. Multivariate analysis was then conducted to assess the independent effects of these variables on overall survival (OS). The most frequent site of PCNSL-DLBCL was confirmed in supratentorial areas, with invasion of midline structures; 7 cases presented with a single lesion, while 11 exhibited multifocal disease. All cases exhibited positive expression of CD20, PAX5 and CD79a; 21 cases exhibited positive expression of BCL2. The mean Ki67 labeling index was 80%. A total of 17 cases were classified as non-GCB and 6 as GCB. A statistically significant association was documented between the site of the disease and the number of lesions (P=0.04), the site of disease and subtype (P=0.03), and the IHC subtype and mean enhancement value (P=0.008). The present study demonstrated that DLBCL with a non-GCB immunohistochemical profile was predominantly observed in patients with unfavorable prognostic factors, such as age >60 years, a high Ki67 labeling index and shorter OS. Statistically significant associations were found between disease location and the number of lesions, disease location and IHC subtype, and between IHC subtype and the mean enhancement value, which may serve as predictors for the IHC subtype. Multivariate analysis and Kaplan-Meier curves revealed that the IHC subtype and enhancement value were independent prognostic factors, with the GCB profile and higher enhancement values being associated with longer OS times and improved prognosis (P=0.0158). In conclusion, the identified associations suggested that the IHC subtype and apparent diffusion coefficient neuroimaging parameters were useful validated prognostic indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.